Who is sponsoring NCT04479111?

NCT04479111 is sponsored by Zhejiang University.

What drugs are being tested in NCT04479111?

Interventions in NCT04479111: laparoscopic ileocecus-sparing right hemicolectomy.

What condition does NCT04479111 study?

NCT04479111 studies Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer.

Is NCT04479111 still recruiting?

NCT04479111 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT04479111: LISH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Laparoscopic IIeocecus-Sparing Right Hemicolectomy for Cancer of the Hepatic Flexure and Proximal Transverse Colon

Completed NA Last updated 8 February 2023

What this trial tests

NA trial testing laparoscopic ileocecus-sparing right hemicolectomy in Hepatic Flexure Colon Cancer in 30 participants. Completed in 1 January 2023.

Timeline

1 January 2020

Primary endpoint
30 December 2022

1 January 2023

Quick facts

Lead sponsor	Zhejiang University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2020
Primary completion	30 December 2022
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

laparoscopic ileocecus-sparing right hemicolectomy

Conditions studied

Hepatic Flexure Colon Cancer — all drugs for Hepatic Flexure Colon Cancer →
Proximal Transverse Colon Cancer — all drugs for Proximal Transverse Colon Cancer →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Hepatic Flexure Colon Cancer or Proximal Transverse Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate whether laparoscopic ileocecus-sparing right hemicolectomy is feasible and oncologically safe

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatic Flexure Colon Cancer

Currently open trials in the same condition.

NCT05923255 — LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer · NA · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04479111 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing